We Can Medicines Co., Ltd.

As of June 30, 2026, We Can Medicines Co., Ltd. carries a market capitalization of 1.07B, placing it among publicly traded companies globally. Its enterprise value stands at 1.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

We Can Medicines Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, We Can Medicines Co., Ltd. has 45.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.33, and the price-to-book ratio stands at 1.06.

As of June 30, 2026, We Can Medicines Co., Ltd. trades at an EV/EBITDA multiple of 8.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.96B versus a market cap of 1.07B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, We Can Medicines Co., Ltd. maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 110.22, indicating elevated leverage, while an interest coverage ratio of 9.83 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, We Can Medicines Co., Ltd. posted a negative return on equity (ROE) of -7.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.66, reflecting losses generated across the asset base. The company generates approximately 3.16M in revenue per employee across its workforce of 1,016.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.56 indicates how many times We Can Medicines Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, We Can Medicines Co., Ltd. recorded 18,000.00 in income tax expense. The company reported a pretax loss of -78.01M and -78.03M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, We Can Medicines Co., Ltd.'s stock has declined approximately 28.45% over the past 52 weeks. The 50-day moving average sits at 22.44, while the 200-day moving average is 27.07.

Over the twelve months ended June 30, 2026, We Can Medicines Co., Ltd. generated 3.21B in revenue and converted that into -78.03M in net income, yielding earnings per share of -1.73. EBITDA reached 243.47M, while operating income came in at -77.13M.

As of June 30, 2026, We Can Medicines Co., Ltd. holds 223.72M in cash and equivalents against 1.11B in total debt, resulting in a net debt position of -85.84M. Total book value stands at 1.01B, with working capital of 449.58M providing operational flexibility.

We Can Medicines Co., Ltd. produced 320.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -38.21M in capital expenditures, free cash flow totaled 282.07M - equivalent to 6.24 per share.

Over the twelve months ended June 30, 2026, We Can Medicines Co., Ltd. posted a gross margin of 32.82, reflecting its pricing power and cost economics. The operating margin of -2.41 and net profit margin of -2.43 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 26.28, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 25.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to We Can Medicines Co., Ltd. shareholders.

As of June 30, 2026, We Can Medicines Co., Ltd. has an Altman Z-Score of 1.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.